Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
- PMID: 10778856
- DOI: 10.1016/S0092-8674(00)80623-6
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
Abstract
Neurodegenerative disorders like Huntington's disease (HD) are characterized by progressive and putative irreversible clinical and neuropathological symptoms, including neuronal protein aggregates. Conditional transgenic models of neurodegenerative diseases therefore could be a powerful means to explore the relationship between mutant protein expression and progression of the disease. We have created a conditional model of HD by using the tet-regulatable system. Mice expressing a mutated huntingtin fragment demonstrate neuronal inclusions, characteristic neuropathology, and progressive motor dysfunction. Blockade of expression in symptomatic mice leads to a disappearance of inclusions and an amelioration of the behavioral phenotype. We thus demonstrate that a continuous influx of the mutant protein is required to maintain inclusions and symptoms, raising the possibility that HD may be reversible.
Comment in
-
Reversing neurodegeneration: a promise unfolds.Cell. 2000 Mar 31;101(1):1-4. doi: 10.1016/S0092-8674(00)80617-0. Cell. 2000. PMID: 10778849 Review. No abstract available.
Similar articles
-
Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45. doi: 10.1098/rstb.1999.0456. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434303 Free PMC article.
-
Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.Neurobiol Dis. 2006 Feb;21(2):381-91. doi: 10.1016/j.nbd.2005.07.014. Epub 2005 Sep 16. Neurobiol Dis. 2006. PMID: 16150600
-
Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.J Neurosci. 2001 Nov 15;21(22):8772-81. doi: 10.1523/JNEUROSCI.21-22-08772.2001. J Neurosci. 2001. PMID: 11698589 Free PMC article.
-
Mutant huntingtin can paradoxically protect neurons from death.Cell Death Differ. 2008 Mar;15(3):435-42. doi: 10.1038/sj.cdd.4402261. Epub 2007 Nov 2. Cell Death Differ. 2008. PMID: 17975550 Review.
-
The use of transgenic and knock-in mice to study Huntington's disease.Cytogenet Genome Res. 2003;100(1-4):276-86. doi: 10.1159/000072863. Cytogenet Genome Res. 2003. PMID: 14526189 Review.
Cited by
-
Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.Drug Des Devel Ther. 2015 Apr 15;9:2179-88. doi: 10.2147/DDDT.S58470. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25931812 Free PMC article. Review.
-
Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator.J Neurosci. 2012 Aug 1;32(31):10574-86. doi: 10.1523/JNEUROSCI.0893-12.2012. J Neurosci. 2012. PMID: 22855807 Free PMC article.
-
A huntingtin peptide inhibits polyQ-huntingtin associated defects.PLoS One. 2013 Jul 4;8(7):e68775. doi: 10.1371/journal.pone.0068775. Print 2013. PLoS One. 2013. PMID: 23861941 Free PMC article.
-
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications.Biomaterials. 2022 Dec;291:121876. doi: 10.1016/j.biomaterials.2022.121876. Epub 2022 Oct 28. Biomaterials. 2022. PMID: 36334354 Free PMC article. Review.
-
Molecular mechanisms underlying nucleotide repeat expansion disorders.Nat Rev Mol Cell Biol. 2021 Sep;22(9):589-607. doi: 10.1038/s41580-021-00382-6. Epub 2021 Jun 17. Nat Rev Mol Cell Biol. 2021. PMID: 34140671 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases